Publication · preprint
Hras G12V induces follicular thyroid cancer with attenuated MAPK activation and increased latency compared to Kras G12D.
Nicholas E Bambach, Katherine Labella, Lee Ann Jolly, Diana Isabel Cruz, Nicole Massol, Antonio Di Cristofano, Aime T Franco
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
RAS mutations are found in nearly 50% of follicular thyroid cancers (FTCs), frequently accompanied by secondary mutations in the PI3K/AKT pathway as tumors advance to more poorly differentiated states. To examine the role that oncogenic Hras plays in thyroid tumor initiation and progression, we…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Thyroid Gland Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available